C, OCN, discusses planning beyond first-line CDK4/6 inhibitors and supportive care strategies for patients with HR+/HER2– ...

Subcutaneous daratumumab is well tolerated, but ongoing immune monitoring is key to managing infection risk in patients with ...

An LED-based intraoral device for photobiomodulation therapy was safe and reduced severe oral mucositis in patients with head ...

The REMS program for vandetanib in the treatment of patients with medullary thyroid cancer has been removed by the FDA.

Leaders in oncology nursing and advanced practice spotlight the essential role of advanced practice providers in oncology.

BC, AOCNP, explains how ctDNA can inform prognosis, monitor disease progression, and guide treatment decisions in oncology.

The FDA has approved imlunestrant for the treatment of patients with ESR1-mutated ER+, HER2- metastatic breast cancer.

Caleb Raine, PA-C explains what BCMA is and why it is a common bispecific antibody target in multiple myeloma.

The NCCN has added revumenib (Revuforj) to its guidelines for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) harboring NPM1 mutations, accordin ...

Tepotinib was associated with frequent but manageable adverse events in MET exon 14–positive NSCLC, with peripheral edema most common. A pooled analysis of cohorts A and C from the phase 2 VISION ...

Formerly known as TAR-200, gemcitabine intravesical system has received the FDA’s approval for use in patients with BCG-unresponsive NMIBC. The FDA has granted approval to gemcitabine intravesical ...